{
  "docId": "019de071-38a0-778d-8d39-45a206af86ac",
  "docSlug": "8e68c7763c84d1b485e12f828c3b0d7e",
  "documentTitle": "argenx SE | Investor Day Presentation Deck | 69 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 69,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-38a0-778d-8d39-45a206af86ac/22",
  "deckHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac",
  "deckJsonHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac.json",
  "deckAnchorHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.58,
        "y": 0.25
      },
      "kind": "callout",
      "text": "No evidence of dose-limiting toxicities in healthy volunteers or patients across trials. Opportunity to dose efgartigimod to maximum PD effect",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e7544df-e332-40a3-b9d8-8c9b34227e73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.1,
        "x": 0.15,
        "y": 0.45
      },
      "kind": "metric",
      "text": "125+",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bffa82b-9810-41cd-ba4a-5da9ab8b989e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.1,
        "x": 0.15,
        "y": 0.25
      },
      "kind": "metric",
      "text": "600+",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84eb44cf-8483-4d33-b9fc-49408e5e5a15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.1,
        "x": 0.15,
        "y": 0.65
      },
      "kind": "metric",
      "text": "100",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96711328-0632-4a9a-aad8-135feb284e29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.08,
        "y": 0.73
      },
      "kind": "paragraph",
      "text": "patients on efgartigimod for over 18 months",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0739efac-55e9-454e-a1e6-d0ea45a2bc7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.32,
        "y": 0.38
      },
      "kind": "paragraph",
      "text": "Clinical proof-of-concept in four indications (MG, ITP, PV, CIDP)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46813b5b-70a0-4d50-86d0-aec495cebf1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.08,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "patients on efgartigimod for over 12 months",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ca75643-8bd5-412c-b694-5dc88ba1cb46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.13,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "subjects dosed",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5465f20e-6b40-4011-8606-056113c4c2c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Efgartigimod: Data Support Favorable Benefit to Risk Ratio",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88db0761-2636-4c4b-b26a-eeed715978f6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}